RxDoctor Payments Data

Richard Gruen, MD

Ophthalmology · Owings Mills, MDNPI 1043221088

Payments from drug & device makers

$980in general payments, 2019–2025

Across 26 payments — averaging $37.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$318
  • Alcon$231
  • Sun Pharmaceutical Industries Inc.$168
  • AbbVie$67
  • Carl Zeiss Meditec, Inc.$65
  • Boston Scientific$33
  • plus $98 from 5 others

What the payments were for

  • Food & beverage$96098%
  • Gifts$192%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$980 in reported general payments places this provider in the 45th percentile of 493 ophthalmology providers in Maryland.

See all ophthalmology providers in Maryland

Medicare billing

Part B allowed, 2024
$290,145
Medicare patients
1,075
Services billed
2,629

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Latanoprost741$13,190
Travoprost39$11,900
MieboPerfluorohexyloctane/Pf12$8,884
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat319$8,272
SimbrinzaBrinzolamide/Brimonidine Tart20$8,265
LumiganBimatoprost19$7,506
Pilocarpine Hcl69$4,639
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol23$4,214
Brimonidine Tartrate89$3,171
Dorzolamide-TimololDorzolamide/Timolol/Pf24$2,737
Prednisolone Acetate76$2,643
Tobramycin-DexamethasoneTobramycin/Dexamethasone48$2,528
Bromfenac Sodium11$2,183
Dorzolamide Hcl65$1,995
Olopatadine Hcl13$1,036

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Miebo$318$8,88412 claims
AlconSimbrinza$231$8,26520 claims
AbbVieLumigan$67$7,50619 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 493 ophthalmology providers in Maryland.

Other ophthalmology in Owings Mills

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →